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Resolution of Clinical Signs in Trauma Intensive Care Unit Patients
Following Diagnosis of Ventilator-Associated Pneumonia
Abstract
PURPOSE: The ATS/IDSA Ventilator-Associated Pneumonia (VAP) guidelines suggest that clinical
improvement of VAP should be apparent within 3-6 days. Anecdotally, such improvement has not been noted
in trauma patients at our institution. The current study was conducted to evaluate resolution of clinical signs
of VAP following diagnosis.
METHODS: Critically injured adults admitted to the trauma intensive care unit (TICU) from 6/1/06-12/
31/07 and subsequently diagnosed with VAP were retrospectively reviewed. Clinical signs, including
derangements of maximum temperature (Tmax), white blood cell (WBC) count and Pa02/FiO2, were
evaluated on days 1-16 following VAP diagnosis. Data are presented as mean ± SD unless otherwise stated.
Clinical parameters following VAP were compared using repeated measures ANOVA with the Tukey test for
multiple comparisons.
RESULTS: A total of 82 patients were identified. Data for the 34 patients without concurrent infections are
presented. Demographic data include: Age 46 ± 17 years; 71% males; 94% blunt trauma; median (IQR)
Injury Severity Score 29.5 (24 to 38); duration of mechanical ventilation 33 ± 27 days; ICU length of stay
(LOS) 39 ± 25 days; hospital LOS 53 ± 33 days. Clinical signs following VAP diagnosis (Figure): Tmax (°F):
Day 1=101.8 ± 1.3, Day 3=101.1 ± 1.1, Day 6=101.1 ± 1.4, Day 16=100.1 ± 3. Compared to Day 1, there was a
significant reduction in Tmax at Days 10, 11, 12, 13, 14 and 16 (p < 0.05 for all). WBC count (cells/μL): Day
1=12.9 ± 5, Day 3=13.7 ± 5, Day 6=14.4 ± 5, Day 16=13.8 ± 6. There was no significant difference in WBC
count on Days 1-16 (p=0.42). PaO2/FiO2: Day 1=232 ± 108, Day 3=200 ± 87, Day 6=218 ± 104, Day
16=246 ± 126. Differences in PaO2/FiO2 on Days 1-16 did not reach statistical significance (p=0.06).
CONCLUSIONS: In trauma patients, improvement of clinical parameters following diagnosis of VAP is
delayed beyond the 3-6 day timeframe suggested in the ATS/IDSA guidelines. Alternative methods for
determining resolution of VAP in trauma patients should be investigated. METHODS INTRODUCTION
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CONCLUSIONS 
PURPOSE:  The ATS/IDSA Ventilator-Associated Pneumonia (VAP) guidelines suggest that clinical 
improvement of VAP should be apparent within 3-6 days. Anecdotally, such improvement has not been noted 
in trauma patients at our institution. The current study was conducted to evaluate resolution of clinical signs 
of VAP following diagnosis. 
METHODS: Critically injured adults admitted to the trauma intensive care unit (TICU) from 6/1/06-12/31/07 
and subsequently diagnosed with VAP were retrospectively reviewed. Clinical signs, including derangements 
of maximum temperature (Tmax), white blood cell (WBC) count and Pa02/FiO2, were evaluated on days 1-
16 following VAP diagnosis. Data are presented as mean ± SD unless otherwise stated. Clinical parameters 
following VAP were compared using repeated measures ANOVA with the Tukey test for multiple 
comparisons. 
RESULTS: A total of 82 patients were identified. Data for the 34 patients without concurrent infections are 
presented.  Demographic data include: Age 46 ± 17 years; 71% males; 94% blunt trauma; median (IQR) 
Injury Severity Score 29.5 (24 to 38); duration of mechanical ventilation 33 ± 27 days; ICU length of stay 
(LOS) 39 ± 25 days; hospital LOS 53 ± 33 days. Clinical signs following VAP diagnosis (Figure): Tmax (°F): 
Day 1=101.8 ± 1.3, Day 3=101.1 ± 1.1, Day 6=101.1 ± 1.4, Day 16=100.1 ± 3. Compared to Day 1, there was 
a significant reduction in Tmax at Days 10, 11, 12, 13, 14 and 16 (p < 0.05 for all). WBC count (cells/μL): 
Day 1=12.9 ± 5, Day 3=13.7 ± 5, Day 6=14.4 ± 5, Day 16=13.8 ± 6. There was no significant difference in 
WBC count on Days 1-16 (p=0.42). PaO2/FiO2: Day 1=232 ± 108, Day 3=200 ± 87, Day 6=218 ± 104, Day 
16=246 ± 126. Differences in PaO2/FiO2 on Days 1-16 did not reach statistical significance (p=0.06). 
CONCLUSIONS: In trauma patients, improvement of clinical parameters following diagnosis of VAP is 
delayed beyond the 3-6 day timeframe suggested in the ATS/IDSA guidelines. Alternative methods for 
determining resolution of VAP in trauma patients should be investigated. 
METHODS 
INTRODUCTION 
VAP is the most frequent ICU-acquired infection among 
mechanically ventilated patients, associated with increased 
morbidity, costs and ~30-70% mortality.  The VAP Guidelines use 
clinical parameters to define normal pattern of resolution, i.e., 
WBC (normal: 5-10 cells/µL), temperature (normal: 98.6° F), 
PaO2:FiO2 (normal : 380 -475)1.  These guidelines suggest clinical 
improvement is seen at > 72 hours, and recommend a duration of 
therapy of 7-14 days.  Denneson et al described resolution of VAP 
in a mixed ICU and noted trends of WBC, temperature and 
PaO2:FiO2 over time2.  He found that response occurred in 6 days, 
which is different than the guidelines.  However, trauma patients 
are different, as they have a 2-3x greater incidence of VAP than 
other populations3, and 90%  experience systemic inflammatory 
response syndrome (SIRS) in the 1st week4. 
Design: Retrospective review from pre-existing database  
Inclusion Criteria: Critically injured trauma patients diagnosed 
with VAP 
Exclusion Criteria: Age <18 years, pregnant, 
immunocompromised, immunosuppressed 
Clinical Endpoints: Improvement or resolution of temperature, 
WBC, PaO2: FiO2. 
Statistical analysis: Descriptive Statistics, one-way repeated 
measures ANOVA for daily comparisons of clinical parameters 
 
All patients diagnosed with fiberoptic bronchoscopy, treated 
with current TICU VAP Pathway 
PURPOSE 
Maximum Temperature Over Time 
 
 
 
 
 
 
 
 
 
 
 
PaO2/FiO2  Over Time 
 
Rapid resolution of signs of VAP is not seen in trauma patients as 
suggested by the VAP guidelines, and similar to the results of 
Denneson’s study.  Clinical parameter trends show a slow 
response to appropriate antimicrobial therapy .  Future studies 
should explore other methods to determine clinical response to 
VAP in trauma patients, in order to avoid unnecessary antibiotic 
use and adverse effects and minimize costs. 
 
References: 1. Am J Respir Crit Care Med, 2005; 388-416, 2. A Am J Respir Crit Care Med.  
2001;163:1375. 3. Am J Infect Cont. 2008; 36(9):609-626. 4. J Trauma. 2006;61:310 -317.  
RESULTS 
All Patients 
(n = 82) 
Patients without 
Concurrent 
Infections (n = 34) 
Patients with 
Concurrent 
Infections (n = 48) 
P value 
Age 44 + 17 46 + 17 43 + 17 0.39 
Males/Females 
(% Male) 
60/23 (72) 24/10 (71) 36/13 (73) 0.97 
MOI, (% 
Blunt) 
86 32/2 (94) 39/10 (80) 0.11 
Injury 
Severity Score, 
median (IQR) 
34 (25 to 42) 29.5 (24 to 38) 34 (26 to 42) 0.19 
MV 32 + 32 33 + 27 32 + 36 0.49 
ICU LOS 37 + 31 39 + 25 36 + 34 0.21 
Hospital LOS 51 + 38 53 + 33 49 + 42 0.11 
Mortality, 
Dead/Alive (% 
Mortality) 
16/67 (19) 4/30 (12) 12/37 (25) 0.25 
We were interested in determining if Denneson’s findings could be 
extrapolated to ventilated patients in other settings.  Our purpose 
was to describe resolution of clinical signs of VAP in trauma 
patients.  We  hypothesized that trauma patients have delayed 
resolution of clinical signs of VAP. 
WBC Count Over Time 
Statistically 
significant  
(p<0.05) 
